From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bimagrumab ?
Monoclonal antibody
Source Human
Target ACVR2B
Clinical data
Legal status
CAS number 1356922-05-8
ATC code None
Chemical data
Formula ?

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration.[1]

Bimagrumab is currently entering Phase II development, with some research indicating clinical effects.